Advanced in Fibrolamellar Carcinoma

Dr. Hillel Tobias

Transplant Surgery | Gastroenterology | Internal Medicine
261 East 78th Street, 4th Floor, 
New York, NY 
On Staff At
59 Years of Experience
Advanced in Fibrolamellar Carcinoma
261 East 78th Street, 4th Floor, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hillel Tobias is an Internal Medicine specialist and a Transplant Surgeon in New York, New York. Dr. Tobias has been practicing medicine for over 59 years and is rated as an Advanced provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Washington University
Residency
New York University Langone Medical Center
Specialties
Transplant Surgery
Gastroenterology
Internal Medicine
Licenses
Internal Medicine in NY
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine/Gastroenterology
Fellowships
Mount Sinai Hospital and Medical Center
Hospital Affiliations
Hofstra/Northwell School Of Medicine/Nursing
Lenox Hill Hospital
Transplant Institute
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Northwell Health Center for Liver Disease and Transplantation
261 East 78th Street, 4th Floor, New York, NY 10075

Additional Areas of Focus

Dr. Tobias has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

2 Total Publications

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Journal: Hepatology (Baltimore, Md.)
Published: September 04, 2015
Similar Doctors
Elite in Fibrolamellar Carcinoma
Dr. Gadi Lalazar
Gastroenterology | Hepatology
Elite in Fibrolamellar Carcinoma
Dr. Gadi Lalazar
Gastroenterology | Hepatology
1305 York Ave Fl 4, 
New York, NY 
 (0.3 miles away)
646-962-4000
Languages Spoken:
English

Gadi Lalazar is a Gastroenterologist and a Hepatologist in New York, New York. Dr. Lalazar is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, and Liver Cancer.

Distinguished in Fibrolamellar Carcinoma
Dr. Myron E. Schwartz
Transplant Surgery | General Surgery
Distinguished in Fibrolamellar Carcinoma
Dr. Myron E. Schwartz
Transplant Surgery | General Surgery

Icahn School Of Medicine At Mount Sinai

13516 Roosevelt Ave, 
Flushing, NY 
 (6.9 miles away)
212-241-8035
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Myron Schwartz is a Transplant Surgeon and a General Surgeon in Flushing, New York. Dr. Schwartz is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Fibrolamellar Carcinoma, Hepatectomy, and Liver Transplant.

Distinguished in Fibrolamellar Carcinoma
Dr. Marcelo E. Facciuto
Transplant Surgery | General Surgery
Distinguished in Fibrolamellar Carcinoma
Dr. Marcelo E. Facciuto
Transplant Surgery | General Surgery

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (1.1 miles away)
Languages Spoken:
English
See accepted insurances

Marcelo Facciuto is a Transplant Surgeon and a General Surgeon in New York, New York. Dr. Facciuto is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Liver Transplant, and Hepatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tobias's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 8 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile